Fernando Civeira

List of Publications by Year in Descending Order

152 papers	4,926 citations	33 h-index	66 g-index
171 ext. papers	5,908 ext. citations	4.5 avg, IF	5.2 L-index

#	Paper	IF	Citations
152	Leu22_Leu23 Duplication at the Signal Peptide of PCSK9 Promotes Intracellular Degradation of LDLr and Autosomal Dominant Hypercholesterolemia.. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2022**, 101161ATVBAHA122315499	9.4	0
151	Toxic Metals and Subclinical Atherosclerosis in Carotid, Femoral, and Coronary Vascular Territories: The Aragon Workers Health Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, ATVBAHA121316358	9.4	1
150	MLb-LDLr: A Machine Learning Model for Predicting the Pathogenicity of Missense Variants. *JACC Basic To Translational Science*, **2021**, 6, 815-827	8.7	0
149	Cost-effectiveness evaluation of the use of PCSK9 inhibitors. *Endocrinología Diabetes Y Nutrición (English Ed)*, **2021**, 68, 369-371	0.1	
148	ANGPTL3 gene variants in subjects with familial combined hyperlipidemia. *Scientific Reports*, **2021**, 11, 7002	4.9	3
147	Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia. *Atherosclerosis*, **2021**, 320, 47-52	3.1	2
146	Impact of statin therapy on LDL and non-HDL cholesterol levels in subjects with heterozygous familial hypercholesterolaemia. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 1594-1603	4.5	1
145	SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies. *Biomedicines*, **2021**, 9,	4.8	2
144	Nursing workload. Calculation of cardiovascular risk and therapeutic objectives. *Clínica E Investigación En Arteriosclerosis*, **2021**, 33 Suppl 1, 10-17	1.4	
143	Dysbetalipoproteinemia and other lipid abnormalities related to apo E. *Clínica E Investigación En Arteriosclerosis*, **2021**, 33 Suppl 2, 50-55	1.4	0
142	Evaluación del coste-efectividad de la utilización de los inhibidores de PCSK9. *Endocrinología, Diabetes Y Nutrición*, **2021**, 68, 369-371	1.3	3
141	STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. *Journal of Hepatology*, **2021**, 74, 1429-1441	13.4	10
140	Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia. *Revista Espanola De Cardiologia (English Ed)*, **2021**, 74, 664-673	0.7	2
139	An alcohol-free beer enriched with isomaltulose and a resistant dextrin modulates gut microbiome in subjects with type 2 diabetes mellitus and overweight or obesity: a pilot study. *Food and Function* , **2021**, 12, 3635-3646	6.1	7
138	Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. *Atherosclerosis*, **2021**,	3.1	3
137	Effect of Lifestyle Intervention in the Concentration of Adipoquines and Branched Chain Amino Acids in Subjects with High Risk of Developing Type 2 Diabetes: Feel4Diabetes Study. *Cells*, **2020**, 9,	7.9	4
136	Quantifying Thyroid Hormone Resistance in Obesity. *Obesity Surgery*, **2020**, 30, 2411-2412	3.7	

135	Rendimiento diagnóstico de la secuenciación de genes de hipercolesterolemia familiar en sujetos con hipercolesterolemia primaria. *Revista Espanola De Cardiologia*, **2020**, 74, 664-664	1.5	1
134	Effect of bergamot on lipid profile in humans: A systematic review. *Critical Reviews in Food Science and Nutrition*, **2020**, 60, 3133-3143	11.5	11
133	Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia. *European Journal of Preventive Cardiology*, **2020**, 27, 1649-1660	3.9	4
132	Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia. *Atherosclerosis*, **2020**, 292, 143-151	3.1	15
131	Genetic Confirmation of Monogenic Familial Hypercholesterolemia Advises a More Intensive Lipid-Lowering Approach. *JAMA Cardiology*, **2020**, 5, 1452-1453	16.2	
130	Glycerol kinase deficiency in adults: Description of 4 novel cases, systematic review and development of a clinical diagnostic score. *Atherosclerosis*, **2020**, 315, 24-32	3.1	3
129	Papel de los lípidos en la ateroesclerosis. *Revista Espanola De Cardiologia Suplementos*, **2020**, 20, 2-7	0.2	
128	High-density lipoprotein characteristics and coronary artery disease: a Mendelian randomization study. *Metabolism: Clinical and Experimental*, **2020**, 112, 154351	12.7	10
127	High-protein energy-restricted diets induce greater improvement in glucose homeostasis but not in adipokines comparing to standard-protein diets in early-onset diabetic adults with overweight or obesity. *Clinical Nutrition*, **2020**, 39, 1354-1363	5.9	4
126	Effect of an alcohol-free beer enriched with isomaltulose and a resistant dextrin on insulin resistance in diabetic patients with overweight or obesity. *Clinical Nutrition*, **2020**, 39, 475-483	5.9	14
125	Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene. *Atherosclerosis*, **2019**, 282, 143-147	3.1	10
124	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019. *Clínica E Investigación En Arteriosclerosis*, **2019**, 31, 128-139	1.4	13
123	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. *Atherosclerosis*, **2019**, 287, 89-92	3.1	20
122	The island of Gran Canaria: A genetic isolate for familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2019**, 13, 618-626	4.9	8
121	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. *New England Journal of Medicine*, **2019**, 381, 531-542	59.2	192
120	Genetic predictors of weight loss in overweight and obese subjects. *Scientific Reports*, **2019**, 9, 10770	4.9	14
119	Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. *Clínica E Investigación En Arteriosclerosis (English Edition)*, **2019**, 31, 128-139	0.3	
118	Standards for global cardiovascular risk management arteriosclerosis. *Clínica E Investigación En Arteriosclerosis*, **2019**, 31 Suppl 1, 1-43	1.4	1

117	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. *Atherosclerosis*, **2019**, 289, 162-172	3.1	12
116	Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. *Atherosclerosis*, **2019**, 284, 245-252	3.1	34
115	Lipid Profile Rather Than the Mutation Explains Renal Disease in Familial LCAT Deficiency. *Journal of Clinical Medicine*, **2019**, 8,	5.1	6
114	Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy. *Journal of Clinical Medicine*, **2019**, 8,	5.1	7
113	Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. *Lipids in Health and Disease*, **2019**, 18, 216	4.4	6
112	Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome. *Diabetes Care*, **2019**, 42, 303-310	14.6	30
111	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. *Journal of Clinical Lipidology*, **2018**, 12, 920-927.e4	4.9	59
110	Variantes de un solo nucleótido asociadas con la hipercolesterolemia poligénica en familias diagnosticadas de hipercolesterolemia familiar. *Revista Espanola De Cardiologia*, **2018**, 71, 351-356	1.5	7
109	Different protein composition of low-calorie diet differently impacts adipokine profile irrespective of weight loss in overweight and obese women. *Nutrition, Metabolism and Cardiovascular Diseases*, **2018**, 28, 133-142	4.5	6
108	Sleep duration and subclinical atherosclerosis: The Aragon Workers' Health Study. *Atherosclerosis*, **2018**, 274, 35-40	3.1	5
107	Single Nucleotide Variants Associated With Polygenic Hypercholesterolemia in Families Diagnosed Clinically With Familial Hypercholesterolemia. *Revista Espanola De Cardiologia (English Ed)*, **2018**, 71, 351-356	0.7	3
106	Efficacy of repeated phlebotomies in hypertriglyceridemia and iron overload: A prospective, randomized, controlled trial. *Journal of Clinical Lipidology*, **2018**, 12, 1190-1198	4.9	4
105	Association between non-cholesterol sterol concentrations and Achilles tendon thickness in patients with genetic familial hypercholesterolemia. *Journal of Translational Medicine*, **2018**, 16, 6	8.5	8
104	Familial hypercholesterolaemia in childhood: Success starts here. *Clínica E Investigación En Arteriosclerosis (English Edition)*, **2018**, 30, 179-180	0.3	
103	Cholesterol oversynthesis markers define familial combined hyperlipidemia versus other genetic hypercholesterolemias independently of body weight. *Journal of Nutritional Biochemistry*, **2018**, 53, 48-57	6.3	10
102	Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition. *PLoS ONE*, **2018**, 13, e0204771	3.7	
101	Disappearance of recurrent pancreatitis after splenectomy in familial chylomicronemia syndrome. *Atherosclerosis*, **2018**, 275, 342-345	3.1	1
100	Energy-restricted, high-protein diets more effectively impact cardiometabolic profile in overweight and obese women than lower-protein diets. *Clinical Nutrition*, **2017**, 36, 371-379	5.9	20

99	Asociación de la presencia de placa carotídea en la aparición de eventos cardiovasculares en pacientes con hipercolesterolemias genéticas. *Revista Espanola De Cardiologia*, **2017**, 70, 551-558	1.5	7
98	Value of the Definition of Severe Familial Hypercholesterolemia for Stratification of Heterozygous Patients. *American Journal of Cardiology*, **2017**, 119, 742-748	3	14
97	Functional analysis of new 3'untranslated regions genetic variants in genes associated with genetic hypercholesterolemias. *Journal of Clinical Lipidology*, **2017**, 11, 532-542	4.9	5
96	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. *Atherosclerosis*, **2017**, 262, 107-112	3.1	19
95	How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment. *Atherosclerosis Supplements*, **2017**, 26, 25-35	1.7	15
94	Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia. *Atherosclerosis*, **2017**, 263, 92-96	3.1	11
93	Tratamiento de la hipercolesterolemia familiar heterocigota en la infancia y la adolescencia: un problema no resuelto. *Revista Espanola De Cardiologia*, **2017**, 70, 423-424	1.5	3
92	Association Between the Presence of Carotid Artery Plaque and Cardiovascular Events in Patients With Genetic Hypercholesterolemia. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 551-558	0.7	4
91	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. *Journal of Molecular and Cellular Cardiology*, **2017**, 106, 55-67	5.8	34
90	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. *New England Journal of Medicine*, **2017**, 376, 1527-1539	59.2	390
89	ABCG5/G8 gene is associated with hypercholesterolemias without mutation in candidate genes and noncholesterol sterols. *Journal of Clinical Lipidology*, **2017**, 11, 1432-1440.e4	4.9	29
88	The leucine stretch length of PCSK9 signal peptide and its role in development of autosomal dominant hypercholesterolaemia: Unravelling the activities of P.LEU23DEL and P.LEU22_LEU23DUP variants. *Atherosclerosis*, **2017**, 263, e37	3.1	3
87	Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia. *Scientific Reports*, **2017**, 7, 5596	4.9	30
86	Bile acid synthesis precursors in subjects with genetic hypercholesterolemia negative for LDLR/APOB/PCSK9/APOE mutations. Association with lipids and carotid atherosclerosis. *Journal of Steroid Biochemistry and Molecular Biology*, **2017**, 169, 226-233	5.1	5
85	National Dyslipidemia Registry of the Spanish Arteriosclerosis Society: Current status. *Clínica E Investigación En Arteriosclerosis*, **2017**, 29, 248-253	1.4	13
84	Identification and validation of seven new loci showing differential DNA methylation related to serum lipid profile: an epigenome-wide approach. The REGICOR study. *Human Molecular Genetics*, **2016**, 25, 4556-4565	5.6	55
83	Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship. *Circulation: Cardiovascular Genetics*, **2016**, 9, 504-510		44
82	Frequency of rare mutations and common genetic variations in severe hypertriglyceridemia in the general population of Spain. *Lipids in Health and Disease*, **2016**, 15, 82	4.4	16

81	Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes. *Atherosclerosis*, **2016**, 246, 202-7	3.1	11
80	The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 2113-21	5.6	54
79	Femoral and Carotid Subclinical Atherosclerosis Association With Risk Factors and Coronary Calcium: The AWHS Study. *Journal of the American College of Cardiology*, **2016**, 67, 1263-74	15.1	114
78	Rare genetic variants with large effect on triglycerides in subjects with a clinical diagnosis of familial vs nonfamilial hypertriglyceridemia. *Journal of Clinical Lipidology*, **2016**, 10, 790-797	4.9	12
77	Lipid phenotype and heritage pattern in families with genetic hypercholesterolemia not related to LDLR, APOB, PCSK9, or APOE. *Journal of Clinical Lipidology*, **2016**, 10, 1397-1405.e2	4.9	11
76	microRNA expression profile in human coronary smooth muscle cell-derived microparticles is a source of biomarkers. *Clínica E Investigación En Arteriosclerosis*, **2016**, 28, 167-77	1.4	15
75	Rapid resolution of xanthelasmas after treatment with alirocumab. *Journal of Clinical Lipidology*, **2016**, 10, 1259-61	4.9	9
74	IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?. *Atherosclerosis*, **2015**, 240, 161-2	3.1	41
73	Functional characterization and classification of frequent low-density lipoprotein receptor variants. *Human Mutation*, **2015**, 36, 129-41	4.7	35
72	Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. *Circulation*, **2015**, 131, 2104-13	16.7	239
71	Association of ferritin elevation and metabolic syndrome in males. Results from the Aragon WorkersQHealth Study (AWHS). *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 2081-9	5.6	10
70	Circulating soluble low-density lipoprotein receptor-related protein 1 (sLRP1) concentration is associated with hypercholesterolemia: A new potential biomarker for atherosclerosis. *International Journal of Cardiology*, **2015**, 201, 20-9	3.2	27
69	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. *European Heart Journal*, **2015**, 36, 2996-3003	9.5	311
68	Serum plant sterols as surrogate markers of dietary compliance in familial dyslipidemias. *Clinical Nutrition*, **2015**, 34, 490-5	5.9	1
67	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2015**, 385, 331-40	40	493
66	Monogenic Hypercholesterolemias. *Contemporary Endocrinology*, **2015**, 177-203	0.3	
65	Bile acid synthesis precursors in familial combined hyperlipidemia: the oxysterols 24S-hydroxycholesterol and 27-hydroxycholesterol. *Biochemical and Biophysical Research Communications*, **2014**, 446, 731-5	3.4	11
64	The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture. *Journal of Proteomics*, **2014**, 106, 61-73	3.9	24

63	Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. *Metabolism: Clinical and Experimental*, **2014**, 63, 365-71	12.7	13
62	Serum lipid responses to weight loss differ between overweight adults with familial hypercholesterolemia and those with familial combined hyperlipidemia. *Journal of Nutrition*, **2014**, 144, 1219-26	4.1	13
61	Common genetic variants contribute to primary hypertriglyceridemia without differences between familial combined hyperlipidemia and isolated hypertriglyceridemia. *Circulation: Cardiovascular Genetics*, **2014**, 7, 814-21		30
60	Atherosclerosis progression in patients with autosomal dominant hypercholesterolemia in clinical practice. *Journal of Clinical Lipidology*, **2014**, 8, 373-80	4.9	2
59	A genetic variant in the LDLR promoter is responsible for part of the LDL-cholesterol variability in primary hypercholesterolemia. *BMC Medical Genomics*, **2014**, 7, 17	3.7	13
58	Should we forget about low-density lipoprotein cholesterol?. *Journal of the American College of Cardiology*, **2014**, 63, 1228-1229	15.1	10
57	Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. *Circulation*, **2014**, 129, 234-43	16.7	180
56	Severe hypercholesterolemia and phytosterolemia with extensive xanthomas in primary biliary cirrhosis: role of biliary excretion on sterol homeostasis. *Journal of Clinical Lipidology*, **2014**, 8, 520-4	4.9	11
55	Eicosapentaenoic acid in serum phospholipids relates to a less atherogenic lipoprotein profile in subjects with familial hypercholesterolemia. *Journal of Nutritional Biochemistry*, **2013**, 24, 1604-8	6.3	7
54	Simultaneous determination of oxysterols, phytosterols and cholesterol precursors by high performance liquid chromatography tandem mass spectrometry in human serum. *Analytical Methods*, **2013**, 5, 2249	3.2	35
53	The fine line between familial and polygenic hypercholesterolemia. *Clinical Lipidology*, **2013**, 8, 303-306		5
52	Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. *Atherosclerosis*, **2012**, 222, 449-55	3.1	53
51	Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. *Nutrition, Metabolism and Cardiovascular Diseases*, **2012**, 22, 591-7	4.5	30
50	Aragon workersQhealth study--design and cohort description. *BMC Cardiovascular Disorders*, **2012**, 12, 45	2.3	50
49	Age and sex influence the relationship between waist circumference and abdominal fat distribution measured by bioelectrical impedance. *Nutrition Research*, **2012**, 32, 466-9	4	11
48	Omega-3 fatty acids and HDL. How do they work in the prevention of cardiovascular disease?. *Current Vascular Pharmacology*, **2012**, 10, 432-41	3.3	23
47	Association of plasma markers of cholesterol homeostasis with metabolic syndrome components. A cross-sectional study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2011**, 21, 651-7	4.5	21
46	A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22. *Clinical Genetics*, **2011**, 79, 475-81	4	21

45	Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis. *Metabolism: Clinical and Experimental*, **2011**, 60, 830-4	12.7	14
44	New contributions to the study of common double mutants in the human LDL receptor gene. *Die Naturwissenschaften*, **2011**, 98, 943-9	2	4
43	Functional analysis of LDLR promoter and 5QUTR mutations in subjects with clinical diagnosis of familial hypercholesterolemia. *Human Mutation*, **2011**, 32, 868-72	4.7	22
42	The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations. *The Application of Clinical Genetics*, **2010**, 3, 53-64	3.1	36
41	Carotid intima-media thickness in subjects with no cardiovascular risk factors. *Revista Espanola De Cardiologia (English Ed)*, **2010**, 63, 97-102	0.7	20
40	An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. *Nutrition, Metabolism and Cardiovascular Diseases*, **2010**, 20, 236-42	4.5	16
39	Higher incidence of mild cognitive impairment in familial hypercholesterolemia. *American Journal of Medicine*, **2010**, 123, 267-74	2.4	78
38	Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. *Atherosclerosis*, **2010**, 208, 437-41	3.1	35
37	Haplotype analyses, mechanism and evolution of common double mutants in the human LDL receptor gene. *Molecular Genetics and Genomics*, **2010**, 283, 565-74	3.1	6
36	Iron deposits and dietary patterns in familial combined hyperlipidemia and familial hypertriglyceridemia. *Journal of Physiology and Biochemistry*, **2010**, 66, 229-36	5	3
35	Serum ferritin is a major determinant of lipid phenotype in familial combined hyperlipidemia and familial hypertriglyceridemia. *Metabolism: Clinical and Experimental*, **2010**, 59, 154-8	12.7	22
34	Mutations in HFE causing hemochromatosis are associated with primary hypertriglyceridemia. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 4391-7	5.6	15
33	Introducci□ a la gen□tica y su utilidad en el diagn□stico de las enfermedades cardiovasculares: conceptos b□sicos y el ejemplo de la hipercolesterolemia familiar. *Revista Espanola De Cardiologia Suplementos*, **2009**, 9, 14-23	0.2	
32	Overexpression of the CXCL3 gene in response to oxidized low-density lipoprotein is associated with the presence of tendon xanthomas in familial hypercholesterolemia. *Biochemistry and Cell Biology*, **2009**, 87, 493-8	3.6	7
31	Sonographic evaluation of Achilles tendons and carotid atherosclerosis in familial hypercholesterolemia. *Atherosclerosis*, **2009**, 204, 345-7	3.1	17
30	Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. *American Journal of Cardiology*, **2008**, 102, 1187-93, 1193.e1	3	120
29	Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting. *Journal of the American College of Cardiology*, **2008**, 52, 1546-53	15.1	61
28	Sobreexpresi□ g□nica de citocinas proinflamatorias en macr□fagos de sujetos con hipercolesterolemia familiar y xantomas tendinosos. *Cl□nica E Investigaci□n En Arteriosclerosis*, **2008**, 20, 14-21	1.4	

27	Femoral atherosclerosis in heterozygous familial hypercholesterolemia: influence of the genetic defect. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 580-6	9.4	38
26	Genetic Factors of Cardiovascular Diseases **2008**, 44-55		
25	Hyperlipoproteinaemia(a) is a common cause of autosomal dominant hypercholesterolaemia. *Journal of Inherited Metabolic Disease*, **2007**, 30, 970-7	5.4	9
24	Increased intestinal cholesterol absorption in autosomal dominant hypercholesterolemia and no mutations in the low-density lipoprotein receptor or apolipoprotein B genes. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 3667-73	5.6	28
23	Lipoproteínas clásicas, terapéuticas modernas. Farmacología de las lipoproteínas de alta densidad. *Clínica E Investigación En Arteriosclerosis*, **2006**, 18, 10-19	1.4	
22	Tendon xanthomas in familial hypercholesterolemia are associated with a differential inflammatory response of macrophages to oxidized LDL. *FEBS Letters*, **2005**, 579, 4503-12	3.8	46
21	Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response. *American Heart Journal*, **2005**, 150, 1154-62	4.9	15
20	Screening of APOB Gene Mutations in Subjects with Clinical Diagnosis of Familial Hypercholesterolemia. *Human Biology*, **2005**, 77, 663-673	1.2	8
19	The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 2203-8	9.4	56
18	Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1960-5	9.4	75
17	Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. *Human Biology*, **2005**, 77, 663-73	1.2	2
16	Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. *Seminars in Vascular Medicine*, **2004**, 4, 67-74		45
15	Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. *Atherosclerosis*, **2004**, 173, 55-68	3.1	364
14	A common variant in the ABCA1 gene is associated with a lower risk for premature coronary heart disease in familial hypercholesterolaemia. *Journal of Medical Genetics*, **2003**, 40, 163-8	5.8	74
13	Apolipoprotein E genotype is not associated with cardiovascular disease in heterozygous subjects with familial hypercholesterolemia. *American Heart Journal*, **2003**, 145, 999-1005	4.9	16
12	A double mutant [N543H+2393del9] allele in the LDL receptor gene in familial hypercholesterolemia: effect on plasma cholesterol levels and cardiovascular disease. *Human Mutation*, **2002**, 20, 477	4.7	6
11	Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment. *European Journal of Clinical Investigation*, **2002**, 32, 421-8	4.6	22
10	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. *Atherosclerosis*, **2002**, 162, 245-51	3.1	37

9	Analysis of apolipoprotein A-I, lecithin:cholesterol acyltransferase and glucocerebrosidase genes in hypoalphalipoproteinemia. *Atherosclerosis*, **2002**, 163, 49-58	3.1	17
8	The apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. *Atherosclerosis*, **2002**, 165, 127-35	3.1	24
7	Mutation analysis in 36 unrelated Spanish subjects with familial hypercholesterolemia: identification of 3 novel mutations in the LDL receptor gene. *Human Mutation*, **2000**, 15, 483-4	4.7	23
6	A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. *American Journal of Human Genetics*, **1999**, 64, 1378-87	11	126
5	Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. *American Heart Journal*, **1999**, 138, 156-62	4.9	21
4	Identification of recurrent and novel mutations in the LDL receptor gene in Spanish patients with familial hypercholesterolemia. Mutations in brief no. 135. Online. *Human Mutation*, **1998**, 11, 413	4.7	20
3	Identification of recurrent and novel mutations in the LDL receptor gene in Spanish patients with familial hypercholesterolemia. *Human Mutation*, **1998**, 11, 413-413	4.7	25
2	Apo E variants in patients with type III hyperlipoproteinemia. *Atherosclerosis*, **1996**, 127, 273-82	3.1	43
1	Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies. *Atherosclerosis*, **1996**, 122, 33-46	3.1	31